HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by van de Garde, E. M. W. Articles by Leufkens, H. G. M. Search for Related Content PubMed PubMed Citation Articles by van de Garde, E. M. W. Articles by Leufkens, H. G. M.

Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population

¹ Dept of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht, and Depts of ² Clinical Pharmacy, and ³ Pulmonary Diseases, St. Antonius Hospital, Nieuwegein, The Netherlands.

CORRESPONDENCE: E. M. W. van de Garde, Dept of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences (UIPS), Sorbonnelaan 16, 3583 CA Utrecht, The Netherlands. Fax: 31 302539166. E-mail: e.m.w.vandegarde{at}pharm.uu.nl

Keywords: Angiotensin-converting enzyme inhibitor, angiotensin-converting enzyme insertion/deletion polymorphism, pneumonia

Received: September 20, 2005
Accepted January 23, 2006

The aim of the present study was to assess whether the use of angiotensin-converting enzyme (ACE) inhibitors is associated with a decreased risk of hospitalisation for community-acquired pneumonia (CAP) in a general, essentially white population.

Data were obtained from the Dutch PHARMO Record Linkage System. Cases were defined as patients with a first hospital admission for CAP. For each case, up to four population controls were matched by age and sex.

The study population comprised 1,108 patients with a first hospital admission for CAP and 3,817 matched controls. After adjusting for several confounders, ACE inhibitor use was not associated with a decreased incidence of pneumonia (adjusted odds ratio (OR) 1.12; 95% confidence interval (CI) 0.88–1.43). Additionally, no significant association was observed in patients with diabetes, respiratory diseases, heart failure, or patients with both of the last two conditions. Furthermore, adjustment of treatment effects on pneumonia risk using stratification on balancing score also showed no significant association between ACE inhibitor use and pneumonia risk within the different strata (overall adjusted OR 1.09; 95% CI 0.87–1.36).

In contrast with previous findings in Asian populations, the current authors were not able to confirm the beneficial effect of angiotensin-converting enzyme inhibitors on pneumonia risk in a general, essentially white population.

This article has been cited by other articles:

				S. Teramoto, H. Yamamoto, Y. Yamaguchi, Y. Hanaoka, M. Ishii, S. Hibi, and Y. Ouchi ACE inhibitors prevent aspiration pneumonia in Asian, but not Caucasian, elderly patients with stroke Eur. Respir. J., January 1, 2007; 29(1): 218 - 219. [Full Text] [PDF]